Acumen pharmaceuticals to participate in the h.c. wainwright annual global investment conference

Charlottesville, va. and carmel, ind., sept. 06, 2023 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, announced today that management will present at the h.c. wainwright 25th annual global investment conference on wednesday, sept. 13, 2023 at 10:30 a.m. et. the live webcast may be accessed under the investors tab on www.acumenpharm.com and will be archived for 90 days.
ABOS Ratings Summary
ABOS Quant Ranking